TY - JOUR
T1 - Immunoregulatory effects of testosterone supplementation combined with exercise training in men with Inclusion Body Myositis
T2 - a double-blind, placebo-controlled, cross-over trial
AU - Coudert, Jerome D.
AU - Slater, Nataliya
AU - Sooda, Anuradha
AU - Beer, Kelly
AU - Lim, Ee Mun
AU - Boyder, Conchita
AU - Zhang, Rui
AU - Mastaglia, Frank L.
AU - Learmonth, Yvonne C.
AU - Fairchild, Timothy J.
AU - Yeap, Bu B.
AU - Needham, Merrilee
N1 - Funding Information:
We thank all our patients who consented to participate in this study, and their families and carers for supporting their participation, all the members of the Myositis Discovery Programme, Ms Deborah Robertson for liaising with patients and managing appointments, Ms Linda Choo for biological samples registration. Dr Andrew Currie and Ms Chelsea Back for their advice and assistance with the Luminex analysis. We express our gratitude to Lawley Pharmaceuticals Australia (Perth, Western Australia) for packaging and supplying the testosterone and placebo creams and for treatment pack randomisation. We thank PathWest Laboratory medicine WA for creatine kinase testing. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Publisher Copyright:
© 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
PY - 2022
Y1 - 2022
N2 - Objectives: Sporadic Inclusion Body Myositis (IBM) is an inflammatory muscle disease affecting individuals over the age of 45, leading to progressive muscle wasting, disability and loss of independence. Histologically, IBM is characterised by immune changes including myofibres expressing major histocompatibility complex molecules and invaded by CD8+ T cells and macrophages, and by degenerative changes including protein aggregates organised in inclusion bodies, rimmed vacuoles and mitochondrial abnormalities. There is currently no cure, and regular exercise is currently the only recognised treatment effective at limiting muscle weakening, atrophy and loss of function. Testosterone exerts anti-inflammatory effects, inhibiting effector T-cell differentiation and pro-inflammatory cytokine production. Methods: We conducted a double-blind, placebo-controlled, cross-over trial in men with IBM, to assess whether a personalised progressive exercise training combined with application of testosterone, reduced the inflammatory immune response associated with this disease over and above exercise alone. To assess intervention efficacy, we immunophenotyped blood immune cells by flow cytometry, and measured serum cytokines and chemokines by Luminex immunoassay. Results: Testosterone supplementation resulted in modest yet significant count reduction in the classical monocyte subset as well as eosinophils. Testosterone-independent immunoregulatory effects attributed to exercise included altered proportions of some monocyte, T- and B-cell subsets, and reduced IL-12, IL-17, TNF-α, MIP-1β and sICAM-1 in spite of interindividual variability. Conclusion: Overall, our findings indicate anti-inflammatory effects of exercise training in IBM patients, whilst concomitant testosterone supplementation provides some additional changes. Further studies combining testosterone and exercise would be worthwhile in larger cohorts and longer testosterone administration periods.
AB - Objectives: Sporadic Inclusion Body Myositis (IBM) is an inflammatory muscle disease affecting individuals over the age of 45, leading to progressive muscle wasting, disability and loss of independence. Histologically, IBM is characterised by immune changes including myofibres expressing major histocompatibility complex molecules and invaded by CD8+ T cells and macrophages, and by degenerative changes including protein aggregates organised in inclusion bodies, rimmed vacuoles and mitochondrial abnormalities. There is currently no cure, and regular exercise is currently the only recognised treatment effective at limiting muscle weakening, atrophy and loss of function. Testosterone exerts anti-inflammatory effects, inhibiting effector T-cell differentiation and pro-inflammatory cytokine production. Methods: We conducted a double-blind, placebo-controlled, cross-over trial in men with IBM, to assess whether a personalised progressive exercise training combined with application of testosterone, reduced the inflammatory immune response associated with this disease over and above exercise alone. To assess intervention efficacy, we immunophenotyped blood immune cells by flow cytometry, and measured serum cytokines and chemokines by Luminex immunoassay. Results: Testosterone supplementation resulted in modest yet significant count reduction in the classical monocyte subset as well as eosinophils. Testosterone-independent immunoregulatory effects attributed to exercise included altered proportions of some monocyte, T- and B-cell subsets, and reduced IL-12, IL-17, TNF-α, MIP-1β and sICAM-1 in spite of interindividual variability. Conclusion: Overall, our findings indicate anti-inflammatory effects of exercise training in IBM patients, whilst concomitant testosterone supplementation provides some additional changes. Further studies combining testosterone and exercise would be worthwhile in larger cohorts and longer testosterone administration periods.
KW - autoimmunity
KW - clinical trial
KW - exercise therapy
KW - Inclusion Body Myositis
KW - testosterone
UR - https://www.scopus.com/pages/publications/85138823447
U2 - 10.1002/cti2.1416
DO - 10.1002/cti2.1416
M3 - Article
C2 - 36188123
AN - SCOPUS:85138823447
SN - 2050-0068
VL - 11
JO - Clinical and Translational Immunology
JF - Clinical and Translational Immunology
IS - 9
M1 - e1416
ER -